Vernalis plc (VER) Given “Hold” Rating at N+1 Singer
Vernalis plc (LON:VER)‘s stock had its “hold” rating reaffirmed by equities research analysts at N+1 Singer in a research report issued to clients and investors on Thursday. They presently have a GBX 37 ($0.46) price objective on the stock. N+1 Singer’s price target points to a potential upside of 11.28% from the company’s previous close.
Other analysts have also issued research reports about the stock. Panmure Gordon reissued a “buy” rating and issued a GBX 76 ($0.94) price objective on shares of Vernalis plc in a research report on Thursday, September 29th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 99 ($1.23) price objective on shares of Vernalis plc in a research report on Thursday, September 29th. Finally, Canaccord Genuity boosted their price objective on shares of Vernalis plc from GBX 84 ($1.04) to GBX 88 ($1.09) and gave the stock a “buy” rating in a research report on Thursday, September 29th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of GBX 69 ($0.86).
Vernalis plc (LON:VER) opened at 34.0625 on Thursday. Vernalis plc has a 12-month low of GBX 31.00 and a 12-month high of GBX 72.75. The stock’s 50 day moving average is GBX 37.51 and its 200-day moving average is GBX 41.75. The company’s market capitalization is GBX 179.24 million.
In other Vernalis plc news, insider David Mackney sold 27,233 shares of the company’s stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of GBX 39 ($0.48), for a total transaction of £10,620.87 ($13,175.62). Also, insider Carol Ferguson purchased 28,000 shares of the company’s stock in a transaction on Friday, September 30th. The shares were purchased at an average cost of GBX 41 ($0.51) per share, for a total transaction of £11,480 ($14,241.41).
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.